Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD; mirabegron PMR-PASS study group. Hoffman V, et al. Among authors: enger c. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8. Drug Saf. 2021. PMID: 34236595 Free PMC article.
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Ehrenstein V, Huang K, Kahlert J, Bahmanyar S, Karlsson P, Löfling L, Nunes AP, Enger C, Bezemer ID, Kuiper JG, Hoti F, Juuti R, Korhonen P, Mo J, Schachterle SE, Wilner KD, Rørth M, Sørensen HT. Ehrenstein V, et al. Among authors: enger c. Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):758-769. doi: 10.1002/pds.5193. Epub 2021 Jan 24. Pharmacoepidemiol Drug Saf. 2021. PMID: 33428292
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Phiri K, Hallas J, Linder M, Margulis A, Suehs B, Arana A, Bahmanyar S, Hoffman V, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Kristiansen NS, Appenteng K, de Vogel S, Seeger J. Phiri K, et al. Among authors: enger c. Curr Med Res Opin. 2021 May;37(5):867-877. doi: 10.1080/03007995.2021.1891035. Epub 2021 Mar 8. Curr Med Res Opin. 2021. PMID: 33591859
Health outcomes among patients receiving oseltamivir.
Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Enger C, et al. Pharmacoepidemiol Drug Saf. 2004 Apr;13(4):227-37. doi: 10.1002/pds.845. Pharmacoepidemiol Drug Saf. 2004. PMID: 15255089
128 results